Evidence map›Paper›PMID 35626216›Full record

ArticleDiagnostics (Basel, Switzerland)2022

Detection of Unknown and Rare Pathogenic Variants in Antithrombin, Protein C and Protein S Deficiency Using High-Throughput Targeted Sequencing.

Petr Vrtel, Ludek Slavik, Radek Vodicka, Julia Stellmachova, Martin Prochazka, Jana Prochazkova, Jana Ulehlova, Peter Rohon, Tomas Simurda, Jan Stasko and 2 more

Open access · goldAbstract read
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Case Report: Severe protein S deficiency unmasks a crypticFrontiers in cardiovascular medicine · 2026
    Article
  2. Review
  3. Article
  4. Antithrombin Therapy: Current State and Future Outlook.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Petr VrtelDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.ORCID 0000-0002-2374-9095
Ludek SlavikDepartment of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Radek VodickaDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Julia StellmachovaDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Martin ProchazkaDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Jana ProchazkovaDepartment of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Jana UlehlovaDepartment of Hemato-Oncology, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Peter RohonDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
Tomas SimurdaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia.ORCID 0000-0002-7626-9650
Jan StaskoNational Centre of Hemostasis and Thrombosis, Department of Hematology and Transfusiology, Comenius University in Bratislava, Jessenius Faculty of Medicine in Martin and University Hospital in Martin, 03659 Martin, Slovakia.
Ivana MartinkovaHEMACENTRUM spol s.r.o., 32600 Pilsen, Czech Republic.
Radek VrtelDepartment of Medical Genetics, University Hospital Olomouc, 77900 Olomouc, Czech Republic.
University Hospital Olomouc · CZComenius University Bratislava · SK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The deficiency of natural anticoagulants—antithrombin (AT), protein C (PC), and protein S (PS)—is a highly predisposing factor for thrombosis, which is still underdiagnosed at the genetic level. We aimed to establish and evaluate an optimal diagnostic approach based on a high-throughput sequencing platform suitable for testing a small number of genes. A fast, flexible, and efficient method involving automated amplicon library preparation and target sequencing on the Ion Torrent platform was optimized. The cohort consisted of a group of 31 unrelated patients selected for sequencing due to repeatedly low levels of one of the anticoagulant proteins (11 AT-deficient, 13 PC-deficient, and 7 PS-deficient patients). The overall mutation detection rate was 67.7%, highest in PC deficiency (76.9%), and six variants were newly detected—SERPINC1 c.398A > T (p.Gln133Leu), PROC c.450C > A (p.Tyr150Ter), c.715G > C (p.Gly239Arg) and c.866C > G (p.Pro289Arg), and PROS1 c.1468delA (p.Ile490fs) and c.1931T > A (p.Ile644Asn). Our data are consistent with those of previous studies, which mostly used time-consuming Sanger sequencing for genotyping, and the indication criteria for molecular genetic testing were adapted to this process in the past. Our promising results allow for a wider application of the described methodology in clinical practice, which will enable a suitable expansion of the group of indicated patients to include individuals with severe clinical findings of thrombosis at a young age. Moreover, this approach is flexible and applicable to other oligogenic panels.

Indexed as

anticoagulantantithrombin deficiencyhigh-throughput sequencingmutation detection rateNGSprotein C deficiencyprotein S deficiency

Identifiers

PMID35626216
PMCPMC9139221
OpenAlexW4224312032

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.